AN2 Therapeutics is rethinking its business in response to lackluster midphase data, vowing to lay off half its employees and stop a phase 3 study as part of a pivot to early-stage projects.

French preclinical CRO NovAliX has found a new partner across the pond. Massachusetts-based manufacturer Bruker Corporation has announced a minority investment in the CRO.

The FDA is alerting healthcare providers to a medical device recall from Medtronic for its nerve monitoring system that has been linked to 10 injuries.

Cullinan Therapeutics was impressed enough with Harbour BioMed’s bispecific immune activator that it handed over $25 million last year for the drug’s U.S. rights. But, having taken a peek at phase 1 data, Cullinan has had second thoughts.

Pharmaceutical giant Bayer has teamed up with software group Alara Imaging in a bid to help standardize radiation doses used in computed tomography (CT) scans.

Mattress Liquidators has turned Entero Therapeutics white as a sheet. The creditor ordered Entero to repay its loan, prompting the biotech to lay off staff from the CEO down and race to find a way out of its predicament.

Charles River Laboratories has reported its second-quarter earnings, with the CRO seeing revenue decline from $1.06 billion in the second quarter of last year to $1.03 billion. Demand for the company’s services is likely to continue its downward trajectory through the rest of the year, according to an Aug. 7 release.

Fierce Biotech Associate Editor Gabrielle Masson presented the 2024 class of Fierce 15 winners on the floor of the New York Stock Exchange on Wednesday.

Precigen is throwing everything behind a push to bring a noncancerous tumor gene therapy to market, driving it to lay off 20% of its employees and pause a raft of other programs to stretch its limited funds.

Three weeks after Roche’s Genentech unit walked away from an SHP2 inhibitor pact, Relay Therapeutics has confirmed that it won’t be pushing ahead with the asset solo.